UTHR - United Therapeutics Corp

Insider Sale by Patusky Christopher (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Yesterday, Patusky Christopher, serving as Dir at United Therapeutics Corp (UTHR), sold 2,910 shares at $569.00 per share, for a total transaction value of $1,655,790.00. Following this transaction, Patusky Christopher now holds 2,590 shares of UTHR.

This sale represents a 53.00% decrease in Patusky Christopher's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, April 24, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 24, 2026, meaning the disclosure happened on the same day as the trade.

United Therapeutics Corp operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Patusky Christopher

Patusky Christopher

Dir

Christopher Patusky is a seasoned professional serving as Vice Chairman of United Therapeutics Corporation (UTHR) since 2024 and as a Director/Board Member since October 2002.[[1]](https://www.marketscreener.com/insider/CHRISTOPHER-PATUSKY-A04P9D/)[[2]](https://penntoday.upenn.edu/news/patusky-joins-united-therapeutics-board)[[7]](https://unither.com/about-us/leadership) He is also Principal of Patusky Associates LLC since 2012 and Executive Manager of Slater Run Vineyards LLC since 2014, and previously held roles such as Director of Real Estate at the Maryland Department of Transportation (2007-2011) and Executive Director of the Fels Institute of Government (2002-2007).[[1]](https://www.marketscreener.com/insider/CHRISTOPHER-PATUSKY-A04P9D/) Patusky's career includes 12 years practicing law, clerking for Massachusetts Appeals Court judges, working at firms like Hill & Barlow and Mahon, Patusky, Rothblatt & Fisher specializing in litigation and administrative law, and serving as president of the Fairmount Community Development Corporation.[[2]](https://penntoday.upenn.edu/news/patusky-joins-united-therapeutics-board) He holds a bachelor's degree (Phi Beta Kappa) from Northwestern University, a J.D. from Harvard Law School (Nathan Burkan Memorial Copyright Award recipient), and a master's degree from the University of Pennsylvania Fels Institute of Government (Public Financial Management Award).[[1]](https://www.marketscreener.com/insider/CHRISTOPHER-PATUSKY-A04P9D/)[[2]](https://penntoday.upenn.edu/news/patusky-joins-united-therapeutics-board) Recently, as a UTHR insider, he sold shares including 1,000 shares on April 17, 2026, at $578.88 each under a Rule 10b5-1 plan, and earlier transactions worth $1.55 million in March.[[3]](https://www.investing.com/news/insider-trading-news/united-therapeutics-director-sells-155-million-in-stock-93CH-3940879)[[4]](https://www.marketbeat.com/instant-alerts/united-therapeutics-nasdaquthr-director-christopher-patusky-sells-1000-shares-2026-04-17/)[[5]](https://www.stocktitan.net/sec-filings/UTHR/form-4-united-therapeutics-corp-insider-trading-activity-4524bb287fe4.html) His UTHR holdings were valued at approximately $711,473 as of July 2025, with an estimated net worth of at least $2 million as of April 2026.[[1]](https://www.marketscreener.com/insider/CHRISTOPHER-PATUSKY-A04P9D/)[[6]](https://www.gurufocus.com/insider/74252/christopher-patusky)

View full insider profile →

Trade Price

$569.00

Quantity

2,910

Total Value

$1,655,790.00

Shares Owned

2,590

Trade Date

Friday, April 24, 2026

1 days ago

SEC Filing Date

Friday, April 24, 2026

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About United Therapeutics Corp

Company Overview

No company information available
View news mentioning UTHR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5908460

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime